Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DARE NASDAQ:FNCH NASDAQ:RLMD OTCMKTS:ULUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAREDare Bioscience$2.44+1.7%$2.86$2.35▼$4.60$21.60M1.1435,225 shs3,566 shsFNCHFinch Therapeutics Group$13.00-0.6%$13.25$1.27▼$15.85$20.88M1.212,153 shs1,766 shsRLMDRelmada Therapeutics$0.610.0%$0.59$0.24▼$4.47$20.25M0.59969,952 shs31,734 shsULURULURU$0.00$0.10▼$0.79$5.35M-3.136,691 shsN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAREDare Bioscience0.00%+1.27%-25.00%-18.64%-22.33%FNCHFinch Therapeutics Group0.00%-1.52%-4.18%+0.54%+870.15%RLMDRelmada Therapeutics-0.02%-0.97%-26.93%+135.74%-80.87%ULURULURU0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDAREDare Bioscience1.5792 of 5 stars3.35.00.00.00.00.00.0FNCHFinch Therapeutics Group1.0625 of 5 stars0.03.00.00.02.91.70.6RLMDRelmada Therapeutics4.5932 of 5 stars3.15.00.04.40.04.21.3ULURULURUN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAREDare Bioscience 2.50Moderate Buy$12.00391.80% UpsideFNCHFinch Therapeutics Group 0.00N/AN/AN/ARLMDRelmada Therapeutics 2.25Hold$5.00719.67% UpsideULURULURU 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAREDare Bioscience$25.91K833.46N/AN/A($0.69) per share-3.54FNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/ARLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/AULURULURUN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAREDare Bioscience-$4.05M-$0.17N/AN/AN/AN/AN/A-8.14%8/11/2025 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/ARLMDRelmada Therapeutics-$79.98M-$2.51N/AN/AN/AN/A-181.26%-151.23%8/6/2025 (Estimated)ULURULURUN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest ULUR, DARE, FNCH, and RLMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025RLMDRelmada Therapeutics-$0.25N/AN/AN/AN/AN/A5/13/2025Q1 2025DAREDare Bioscience-$0.63-$0.50+$0.13-$0.50$0.60 million$0.03 million5/12/2025Q1 2025RLMDRelmada Therapeutics-$0.31-$0.58-$0.27-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDAREDare BioscienceN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/AULURULURUN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAREDare BioscienceN/A0.560.56FNCHFinch Therapeutics GroupN/A3.873.87RLMDRelmada TherapeuticsN/A5.295.29ULURULURUN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAREDare Bioscience6.70%FNCHFinch Therapeutics Group21.77%RLMDRelmada Therapeutics45.24%ULURULURUN/AInsider OwnershipCompanyInsider OwnershipDAREDare Bioscience4.00%FNCHFinch Therapeutics Group44.90%RLMDRelmada Therapeutics20.70%ULURULURU1.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAREDare Bioscience308.85 million8.50 millionNot OptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataRLMDRelmada Therapeutics1033.19 million26.32 millionOptionableULURULURU230.57 million30.24 millionNot OptionableULUR, DARE, FNCH, and RLMD HeadlinesRecent News About These CompaniesGPs Honor Indigenous Leadership During NAIDOC WeekJuly 7 at 2:50 AM | miragenews.comM‘Unacceptable’: Mutitjulu community waiting 10 years for new housingJuly 3, 2025 | skynews.com.auSIndigenous leaders say Uluru town at centre of Voice Referendum is still waiting for housing after 10 years, as bureaucracy stymies growthJuly 3, 2025 | skynews.com.auSFull 50th NAIDOC schedule for Uluru and Ayers Rock Resort released by Voyages Indigenous TourismJune 30, 2025 | townsvillebulletin.com.auTNT Gov backs brand new five day, four night 54km eco walk at Uluru with $10m loanJune 29, 2025 | ntnews.com.auN10 best Australian road trips to do with a caravanJune 28, 2025 | msn.comUgly fight between ‘radical rock climbers’ and traditional owners over world-famous siteJune 27, 2025 | news.com.auNCLP-Backed Eco Walk Enhances Central Australia ExperienceJune 26, 2025 | miragenews.comMVirgin Australia sale offers deals on flights in and out of the TerritoryJune 23, 2025 | ntnews.com.auNLocal 10’s Eco Hero winner’s adventures continue in the Australian OutbackJune 23, 2025 | local10.comLShadows falling across the landJune 21, 2025 | thewest.com.auTUluru with friendsJune 21, 2025 | thewest.com.auTWinter getaways in Queensland: from Brisbane to Cairns and the Great Barrier Reef plus UluruJune 20, 2025 | theaustralian.com.auJess Mauboy always wanted to be a mum. She didn't expect the way it changed her.June 20, 2025 | msn.comUluru Statement from the Heart: All Aboriginal people need access to education, employment and a safe living environmentsJune 17, 2025 | dailytelegraph.com.auDUluru Australia (Mala Walk) Walking TourJune 16, 2025 | msn.comTake That! How to sell Australia’s Northern TerritoryJune 12, 2025 | ttgmedia.comT10 BEST Places to Visit in Australia in 2024 🇦🇺 | Full Travel Guide by Lloyd & MandyJune 11, 2025 | msn.comDefining Moments in Australian History: Azaria Chamberlain final inquestJune 11, 2025 | australiangeographic.com.auAHelicopter crashes near Uluru with four people on board; two critical, other passengers stableJune 7, 2025 | ntnews.com.auNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeULUR, DARE, FNCH, and RLMD Company DescriptionsDare Bioscience NASDAQ:DARE$2.44 +0.04 (+1.67%) As of 11:15 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.Finch Therapeutics Group NASDAQ:FNCH$13.00 -0.08 (-0.57%) As of 07/7/2025 11:45 AM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Relmada Therapeutics NASDAQ:RLMD$0.61 0.00 (-0.02%) As of 11:11 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.ULURU OTCMKTS:ULURULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
